Treatment of HBV chronic carriers using interferon (IFN)-α or nucleoside/nucleotide analogues fails to suppress viral infection. Type-II IFN-γ has been shown to inhibit HBV replication. The goal of the present work was to evaluate the antiviral efficacy against HBV of a thermostable IFN-γ variant isolated using Massive Mutagenesis® and thermoresistant selection (THR™) technologies.
Methods
The thermostability of wild-type (wt) and S63C IFN-γ was determined in vitro and in vivo. Activation of the IFN-γ responsive element by wt and S63C IFN-γ was tested using a luciferase assay. HepG2.2.15 cells constitutively expressing HBV were used to analyse the antiviral activity of wt and S63C IFN-γ against HBV replication. Intracellular HBV DNA was detected by Southern blot and quantified by real-time PCR analyses.
Results
S63C IFN-γ was shown to be more thermostable and had a longer half-life than wt IFN-γ. Both wt and S63C IFN-γ displayed a similar capacity to activate the IFN pathway. The treatment of HepG2.2.15 cells with wt or S63C IFN-γ induced the inhibition of HBV viral replication. After heating, S63C IFN-γ displayed better conservation of its antiviral activity against HBV when compared with wt IFN-γ.
Conclusions
These results confirm that the THR™ method can be used to isolate mutants with enhanced thermostability and demonstrate that a thermostable IFN-γ variant presents antiviral properties against HBV replication. This molecule could provide a new strategy to treat patients who do not respond to antiviral therapy.
References
1.
LeeW.M.Hepatitis B virus infection.N Engl J Med1997; 337: 1733–1745.
2.
CheminI., ZoulimF.Hepatitis B virus induced hepatocellular carcinoma.Cancer Lett2009; 286: 52–59.
3.
LiangT.J.Hepatitis B: the virus and disease.Hepatology2009; 49 Suppl 5: S13–S21.
4.
PerrilloR.Benefits and risks of interferon therapy for hepatitis B.Hepatology2009; 49 Suppl 5: S103–S111.
5.
DienstagJ.L.Benefits and risks of nucleoside analog therapy for hepatitis B.Hepatology2009; 49 Suppl 5: S112–S121.
6.
ZoulimF., PerrilloR.Hepatitis B: reflections on the current approach to antiviral therapy.J Hepatol2008; 48 Suppl 1: S2–S19.
7.
VilletS., PichoudC., VilleneuveJ.P., TrepoC., ZoulimF.Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.Gastroenterology2006; 131: 1253–1261.
8.
GuidottiL.G., ChisariF.V.Noncytolytic control of viral infections by the innate and adaptive immune response.Annu Rev Immunol2001; 19: 65–91.
9.
WielandS.F., EustaquioA., Whitten-BauerC., BoydB., ChisariF. V.. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.Proc Natl Acad Sci U S A2005; 102: 9913–9917.
10.
SchroderK., HertzogP.J., RavasiT., HumeD.A.Interferon-gamma: an overview of signals, mechanisms and functions.J Leukoc Biol2004; 75: 163–189.
11.
RobekM.D., WielandS.F., ChisariF. V.. Inhibition of hepatitis B virus replication by interferon requires proteasome activity.J Virol2002; 76: 3570–3574.
12.
ParvezM.K., SehgalD., SarinS.K., BasirS.F., JameelS.Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.World J Gastroenterol2006; 12: 3006–3014.
13.
ParkS.G., RyuH.M., LimS.O.Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase.Gastroenterology2005; 128: 2042–2053.
14.
GuidottiL.G., IshikawaT., HobbsM.V.Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.Immunity1996; 4: 25–36.
15.
WielandS., ThimmeR., PurcellR.H., ChisariF.V.Genomic analysis of the host response to hepatitis B virus infection.Proc Natl Acad Sci U S A2004; 101: 6669–6674.
16.
DumortierJ., SchonigK., OberwinklerH.Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice.Gene Ther2005; 12: 668–677.
17.
KlockerU., SchultzU., SchallerH., ProtzerU.Endotoxin stimulates liver macrophages to release mediators that inhibit an early step in hepadnavirus replication.J Virol2000; 74: 5525–5533.
18.
UprichardS.L., WielandS.F., AlthageA., ChisariF.V.Transcriptional and posttranscriptional control of hepatitis B virus gene expression.Proc Natl Acad Sci U S A2003; 100: 1310–1315.
19.
KakumuS., IshikawaT., MizokamiM.Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon.J Med Virol1991; 35: 32–37.
20.
MarcellinP., LoriotM.A., BoyerN.Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects.Hepatology1990; 12: 155–158.
21.
CarrenoV., MorenoA., GalianaF., BartolomeF.J.Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study.J Hepatol1993; 17: 321–325.
22.
MuschE., HogemannB., GerritzenA.Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.Hepatogastroenterology1998; 45: 2282–2294.
23.
GoossensK., HaelewynJ., MeersmanF., De LeyM., HeremansK.Pressure- and temperature-induced unfolding and aggregation of recombinant human interferon-gamma: a Fourier transform infrared spectroscopy study.Biochem J2003; 370: 529–535.
24.
HaelewynJ., MichielsL., VerhaertP.Interaction of truncated human interferon gamma variants with the interferon gamma receptor: crucial importance of Arg-129.Biochem J1997; 324: 591–595.
25.
BumelisV.A., BumelieneZ., GedminieneG.Investigation of thermal stability of recombinant human interferon-gamma.Biologija (Vilnius)2002; 2: 37–41.
26.
MatsumuraM., AibaS.Screening for thermostable mutant of kanamycin nucleotidyltransferase by the use of a transformation system for a thermophile, Bacillus stearothermophilus.J Biol Chem1985; 260: 15298–15303.
27.
HosekiJ., YanoT., KoyamaY., KuramitsuS., KagamiyamaH.Directed evolution of thermostable kanamycin-resistance gene: a convenient selection marker for Thermus thermophilus.J Biochem1999; 126: 951–956.
28.
DelcourtM., inventor; Biométhodes, assignee. Method for selecting stable proteins in non-standard physicochemical conditions (THR). French patent FR2886943/WO 2006/134240 A1. 10 June 2005.
29.
DelcourtM., BlesaS., inventors; Biométhodes, assignee. Method for massive mutagenesis. European patent 1311670 B1/US patent 7202086 B2 2001. 25 August 2000.
30.
SaboulardD., DugasV., JaberM.High-throughput site-directed mutagenesis using oligonucleotides synthesized on DNA chips.Biotechniques2005; 39: 363–368.
31.
SellsM.A., ChenM-L, AcsG.Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepetitis B virus DNA.Proc Natl Acad Sci U S A1987; 84: 1005–1009.
32.
ChautardH., Blas-GalindoE., MenguyT.An activity-independent selection system of thermostable protein variants.Nat Methods2007; 4: 919–921.
33.
DurantelD., Carrouee-DurantelS., Werle-LapostolleB.A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.Hepatology2004; 40: 855–864.
34.
SoussanP., PolJ., GarreauF.Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease.J Infect Dis2008; 198: 218–225.
35.
SethuramanN., StadheimT.A.Challenges in therapeutic glycoprotein production.Curr Opin Biotechnol2006; 17: 341–346.
36.
ShiH., GuanS.H.Increased apoptosis in HepG2.2.15 cells with hepatitis B virus expression by synergistic induction of interferon-gamma and tumour necrosis factor-alpha.Liver Int2009; 29: 349–355.
37.
RockeyD.C.Current and future anti-fibrotic therapies for chronic liver disease.Clin Liver Dis2008; 12: 939–962.
38.
WengH.L., WangB.E., JiaJ.D.Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study.Clin Gastroenterol Hepatol2005; 3: 819–828.
39.
BrownT.D., KoellerJ., BeougherK.A Phase I clinical trial of recombinant DNA gamma interferon.J Clin Oncol1987; 5: 790–798.
40.
GrayP.W., GoeddelD.V.Structure of the human immune interferon gene.Nature1982; 298: 859–863.
41.
PechenovS.E., TikhonovR.V., ShingarovaL.N.Methods for preparation of recombinant cytokine proteins V. mutant analogues of human interferon-gamma with higher stability and activity.Protein Expr Purif2002; 24: 173–180.
42.
GrayP.W., GoeddelD.V.Cloning and expression of murine immune interferon cDNA.Proc Natl Acad Sci U S A1983; 80: 5842–5846.
43.
HeiseT., GuidottiL.G., ChisariF.V.La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA.J Virol1999; 73: 5767–5776.
44.
GuidottiL.G., McClaryH., LoudisJ.M., ChisariF. V.. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice.J Exp Med2000; 191: 1247–1252.
45.
ProtoS., TaylorJ.A., ChokshiS., NavaratnamN., NaoumovN.V.APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of Hepatitis B virus replication.Antiviral Res2008; 78: 260–267.
